ArticleMolecular and cellular pediatrics2026
Soluble mucosal addressin cell adhesion molecule 1 is a biomarker for pediatric ulcerative colitis.
Article in Molecular and cellular pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEnhanced expression of mucosal addressin cell adhesion molecule 1 (MAdCAM-1) on high endothelial venules facilitates lymphocyte migration to sites of intestinal inflammation in inflammatory bowel disease (IBD). This process may be accompanied by increased shedding of soluble MAdCAM-1 (sMAdCAM-1) from endothelial cells. Hence, circulating sMAdCAM-1 may serve as a biomarker of intestinal inflammation in IBD.
resultsThis single-center study enrolled pediatric (n = 32) and adult (n = 73) patients with IBD, as well as healthy controls (n = 56). Serum samples were collected from all participants, and sMAdCAM-1 concentrations were quantified using an ELISA assay. In healthy individuals, sMAdCAM-1 levels were highest in early childhood, declined during adolescence, and were lowest in adulthood. Concentrations of sMAdCAM-1 did not correlate with gut inflammation in pediatric or adult patients with Crohn’s disease (CD). In contrast, significantly increased sMAdCAM-1 levels were observed in adults with severe ulcerative colitis (UC). Moreover, sMAdCAM-1 levels distinguished healthy children from pediatric UC patients.
conclusionsThese findings provide new insights into sMAdCAM-1 as a marker of gut homeostasis and inflammation. Shedding of sMAdCAM-1 decreases during adolescence, and circulating sMAdCAM-1 levels could serve as a biomarker for ulcerative colitis in both pediatric and adult patients, particularly in severe disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.